[go: up one dir, main page]

AR067747A1 - Metodos para producir suspension de aripiprazol y formulacion liofilizada - Google Patents

Metodos para producir suspension de aripiprazol y formulacion liofilizada

Info

Publication number
AR067747A1
AR067747A1 ARP080103307A ARP080103307A AR067747A1 AR 067747 A1 AR067747 A1 AR 067747A1 AR P080103307 A ARP080103307 A AR P080103307A AR P080103307 A ARP080103307 A AR P080103307A AR 067747 A1 AR067747 A1 AR 067747A1
Authority
AR
Argentina
Prior art keywords
suspension
aripiprazole
sterile
spray
primary
Prior art date
Application number
ARP080103307A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR067747A1 publication Critical patent/AR067747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Reivindicacion 1: Un método para producir una suspension de aripiprazol caracterizado porque comprende los pasos de: (a) combinar aripiprazol a granel y un vehículo para formar una suspension primaria; (b) someter la suspension primaria a una primera pulverizacion para formar una suspension secundaria; y (c) someter la suspension secundaria a una segunda pulverizacion para formar una suspension final. Reivindicacion 12: El método de acuerdo con la reivindicacion 1, caracterizado porque el vehículo contiene al menos un agente de suspension seleccionado del grupo integrado por carboximetil celulosa, sales de carboximetil celulosa, hidroxipropil celulosa, hidroxipropiletil celulosa, hidroxipropilmetil celulosa y polivinil pirrolidona. Reivindicacion 21: El método de acuerdo con la reivindicacion 1 caracterizado porque comprende los pasos de: (1) combinar aripiprazol a granel estéril con un tamano de partícula medio de 200 micrometros hasta 400 micrometros y un vehículo estéril para formar una suspension primaria estéril; (2) someter la suspension primaria estéril a una primera pulverizacion utilizando una máquina de pulverizacion de alto cizallamiento o una máquina de dispersion que aplica fuerza de corte a un material a ser procesado, para formar una suspension secundaria estéril; y (3) someter la suspension secundaria estéril a una segunda pulverizacion utilizando un homogenizador de alta presion para formar una suspension final estéril; donde el aripiprazol en la suspension final estéril tiene un tamano de partícula medio del hasta 10 micrometros. Reivindicacion 24: Un método para producir una formulacion liofilizada de hidrato de aripiprazol A, caracterizado porque comprende los pasos de: enfriar la suspension producida por el método de acuerdo con la reivindicacion 1 y que contiene hidrato de aripiprazol A, hasta -20 hasta - 55°C para congelar la suspension; y a continuacion llevar a cabo el secado por debajo de aproximadamente 0°C. Reivindicacion 25: Un método para producir una formulacion liofilizada que contiene aripiprazol en forma anhidra, caracterizado porque comprende los pasos de: (1) enfriar la suspension de aripiprazol producida por el método de acuerdo con la reivindicacion 1 utilizando aripiprazol a granel en la forma de un monohidrato o cristales anhidros hasta -20 hasta -55°C para congelar la suspension; (2) llevar a cabo secado primario por debajo de aproximadamente 0°C; y (3) llevar a cabo secado secundario por encima de aproximadamente 0°C.
ARP080103307A 2007-07-31 2008-07-30 Metodos para producir suspension de aripiprazol y formulacion liofilizada AR067747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31

Publications (1)

Publication Number Publication Date
AR067747A1 true AR067747A1 (es) 2009-10-21

Family

ID=39816777

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103307A AR067747A1 (es) 2007-07-31 2008-07-30 Metodos para producir suspension de aripiprazol y formulacion liofilizada
ARP180103082A AR117941A2 (es) 2007-07-31 2018-10-23 Métodos para producir suspensión de aripiprazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180103082A AR117941A2 (es) 2007-07-31 2018-10-23 Métodos para producir suspensión de aripiprazol

Country Status (27)

Country Link
US (7) US9457026B2 (es)
EP (1) EP2170279B1 (es)
JP (1) JP4879349B2 (es)
KR (1) KR101546106B1 (es)
CN (1) CN101801342B (es)
AR (2) AR067747A1 (es)
CA (1) CA2695178C (es)
CO (1) CO6290634A2 (es)
CY (1) CY1120165T1 (es)
DK (1) DK2170279T3 (es)
ES (1) ES2661037T3 (es)
HR (1) HRP20180295T1 (es)
HU (1) HUE036214T2 (es)
IL (2) IL244186A0 (es)
LT (1) LT2170279T (es)
MX (1) MX2010001311A (es)
MY (1) MY152789A (es)
NO (1) NO2170279T3 (es)
NZ (1) NZ582415A (es)
PL (1) PL2170279T3 (es)
PT (1) PT2170279T (es)
RU (1) RU2483711C2 (es)
SI (1) SI2170279T1 (es)
TW (1) TWI410255B (es)
UA (1) UA97286C2 (es)
WO (1) WO2009017250A1 (es)
ZA (1) ZA201000307B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
NZ603076A (en) * 2010-08-24 2014-12-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
ES2884825T3 (es) * 2011-01-24 2021-12-13 Otsuka Pharma Co Ltd Dispositivo médico que contiene una composición de torta que comprende aripiprazol como principio activo y composición de torta que comprende aripiprazol como principio activo
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
US20190160002A1 (en) 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
US10821200B2 (en) * 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
US20230310417A1 (en) * 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115364049A (zh) * 2021-05-18 2022-11-22 苏州恩华生物医药科技有限公司 一种月桂酰阿立哌唑混悬剂的制备方法
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
ES2078447T3 (es) 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
JP4142095B2 (ja) 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
US6271208B1 (en) 1996-08-26 2001-08-07 Transgene S.A. Process of making cationic lipid-nucleic acid complexes
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
DE69929959T2 (de) 1998-03-30 2006-11-02 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
ATE355856T1 (de) 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000072835A2 (en) * 1999-05-27 2000-12-07 El Khoury George F Topical application of muscarinic and opioid agents for treatment of tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en) 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
SK14852002A3 (sk) 2000-03-27 2003-06-03 The Scripps Research Institute Spôsoby inhibície angiogenézy a rastu tumoru
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
MXPA03011538A (es) 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
ATE381924T1 (de) 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA2492488A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
UA79984C2 (en) 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
WO2004060351A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
AU2004285595A1 (en) 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
US8182792B2 (en) * 2004-03-23 2012-05-22 Novartis Ag Pharmaceutical compositions
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
AU2006224759A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CA2628716C (en) 2005-11-10 2016-09-27 Alphapharm Pty Ltd Process to control particle size
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法

Also Published As

Publication number Publication date
NO2170279T3 (es) 2018-05-26
NZ582415A (en) 2012-05-25
PL2170279T3 (pl) 2018-05-30
US9457026B2 (en) 2016-10-04
RU2009149820A (ru) 2011-09-10
KR101546106B1 (ko) 2015-08-20
US20200246333A1 (en) 2020-08-06
JP2010535151A (ja) 2010-11-18
TWI410255B (zh) 2013-10-01
US20170035752A1 (en) 2017-02-09
EP2170279B1 (en) 2017-12-27
CA2695178C (en) 2015-06-23
US20100196486A1 (en) 2010-08-05
CN101801342A (zh) 2010-08-11
IL244231A0 (en) 2016-04-21
KR20100057020A (ko) 2010-05-28
IL244186A0 (en) 2016-04-21
MX2010001311A (es) 2010-04-21
ES2661037T3 (es) 2018-03-27
RU2483711C2 (ru) 2013-06-10
BRPI0815382A2 (pt) 2015-02-10
US20210361646A1 (en) 2021-11-25
CA2695178A1 (en) 2009-02-05
JP4879349B2 (ja) 2012-02-22
CY1120165T1 (el) 2018-12-12
ZA201000307B (en) 2011-04-28
US20240139177A1 (en) 2024-05-02
AU2008283251A1 (en) 2009-02-05
DK2170279T3 (en) 2018-03-12
LT2170279T (lt) 2018-03-12
SI2170279T1 (en) 2018-04-30
US20250302826A1 (en) 2025-10-02
PT2170279T (pt) 2018-04-06
HRP20180295T1 (hr) 2018-03-23
EP2170279A1 (en) 2010-04-07
TW200922636A (en) 2009-06-01
WO2009017250A1 (en) 2009-02-05
UA97286C2 (ru) 2012-01-25
MY152789A (en) 2014-11-28
HUE036214T2 (hu) 2018-06-28
CO6290634A2 (es) 2011-06-20
AR117941A2 (es) 2021-09-08
CN101801342B (zh) 2012-07-11
US20180185358A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
AR067747A1 (es) Metodos para producir suspension de aripiprazol y formulacion liofilizada
UY33437A (es) Dispersiones solidas que contienen inhibidores de quinasas
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
BR112015028208A2 (pt) composição de fraturamento hidráulico, método para fabricar e uso da mesma
BR112014009197A8 (pt) métodos de fabricação de filamento contínuo volumoso para tapete, extrusor para uso na extrusão de massa fundida polimérica e filamento contínuo volumoso para tapete
AR083928A1 (es) Metodos para crear fracturas de alta conductividad que conectan redes de fracturas hidraulicas en un pozo
JP2011518842A5 (es)
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
BRPI1012959A8 (pt) Dispersoes solidas contendo um agente promotor de apoptose
WO2011139701A3 (en) Methods and systems for tracking occurrences and non-occurrences of medical-related events
GB2555035A (en) System and method for recording events that occur during a medial procedure, including events associated with the inventorying of articles used during the
BR112015005396A2 (pt) dispositivo inviolável antirefil que dispensa encaixe para um recipiente
BR112013022431A2 (pt) derivado de polissacarídeo, forma de dosagem, processo para preparar uma forma de dosagem e uso de um derivado de polissacarídeo
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
NZ601000A (en) Calcipotriol monohydrate nanocrystals
CN103025318A (zh) 含有喹啉酮衍生物、和硅油和/或硅油衍生物的悬浮液和块状组合物
NI201500028A (es) Formulación de una cápsula farmacéutica compuesta que comprende irbesartan e inhibidor de la hmg-coa reductasa.
ECSP077263A (es)
MX342397B (es) Uso de fluido viscoelastico para producir un producto medicinal para tratar quirurgicamente el ojo.
AR060733A1 (es) Proceso para la precipitacion y el aislamiento de compuestos de 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen los mismos
ES2535862T3 (es) Método para la preparación de productos farmacéuticos
BR112017010283A2 (pt) aparelho de penteado a vapor com invólucro melhorado

Legal Events

Date Code Title Description
FC Refusal